The U.S. Food and Drug Administration approved Viekira Pak to treat patients with chronic hepatitis C virus, including those with cirrhosis.
Viekira Pak contains three new drugs — ombitasvir, paritaprevir and dasabuvir — that work together to inhibit the growth of HCV. It also contains ritonavir, a previously approved drug. The efficacy of the drug was evaluated in six clinical trials enrolling 2,308 participants. However, the most common side effects reported by clinical trial participants were feeling tired, itching, feeling weak or lack of energy, nausea and having trouble sleeping.
Viekira Pak is marketed by AbbVie.
More articles on gastroenterology:
gMed completes initial adoption of ASGE/ACG colonoscopy quality metrics
Covidien's capsule endoscopy featured in Cooper Hewitt exhibit in New York
Is anesthesia dosage adjusted appropriately for different ages? Study says no